MA50201A - Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants - Google Patents

Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants

Info

Publication number: MA50201A
Authority: MA; Morocco
Prior art keywords: deferiprone; delayed; related methods; release tablets; tablets
Prior art date: 2017-10-25

Application number

MA050201A

Other languages

English (en)

Inventor

Michael Spino

Original Assignee

Chiesi Farm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-10-25

Filing date

2018-10-25

Publication date

2021-04-28

2018-10-25 Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa

2021-04-28 Publication of MA50201A publication Critical patent/MA50201A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Psychology (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Toxicology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MA050201A 2017-10-25 2018-10-25 Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants MA50201A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762577055P	2017-10-25	2017-10-25
US201762596043P	2017-12-07	2017-12-07

Publications (1)

Publication Number	Publication Date
MA50201A true MA50201A (fr)	2021-04-28

Family

ID=66170815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050201A MA50201A (fr)	2017-10-25	2018-10-25	Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants

Country Status (17)

Country	Link
US (8)	US20200253945A1 (fr)
EP (1)	EP3684344A4 (fr)
JP (1)	JP7246384B2 (fr)
KR (1)	KR102624627B1 (fr)
CN (2)	CN114533689A (fr)
AU (1)	AU2018357350B2 (fr)
BR (1)	BR112020008128A2 (fr)
CA (2)	CA3077514C (fr)
IL (1)	IL273955A (fr)
MA (1)	MA50201A (fr)
MX (1)	MX2020004107A (fr)
NZ (1)	NZ763555A (fr)
PH (1)	PH12020550815A1 (fr)
SA (1)	SA520411808B1 (fr)
SG (1)	SG11202003153TA (fr)
UA (1)	UA126977C2 (fr)
WO (1)	WO2019082128A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN114533689A (zh)	2017-10-25	2022-05-27	奇斯药制品公司	延迟释放去铁酮片剂及其使用方法
US12016850B2 (en)	2022-04-11	2024-06-25	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
WO2023198640A1 (fr)	2022-04-11	2023-10-19	Chiesi Farmaceutici S.P.A.	Formulations pharmaceutiques à libération modifiée comprenant de la défériprone
US12016851B2 (en)	2022-04-11	2024-06-25	Chiesi Farmaceutici S.P.A.	Modified release pharmaceutical formulations comprising deferiprone
WO2023198641A1 (fr)	2022-04-11	2023-10-19	Chiesi Farmaceutici S.P.A.	Formulations pharmaceutiques à libération modifiée comprenant de la défériprone
WO2024079303A1 (fr) *	2022-10-14	2024-04-18	Chiesi Farmaceutici S.P.A.	Formulations pharmaceutiques à libération modifiée comprenant de la défériprone

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FI98343C (fi) *	1995-03-21	1997-06-10	Orion Yhtymae Oy	Peroraalinen formulaatio
US5747532A (en)	1995-11-21	1998-05-05	Medinox, Inc.	Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor
GB9625638D0 (en)	1996-12-10	1997-01-29	Cenes Ltd	Therapeutic antioxidants for alzheimer's diease
AU2609601A (en)	1999-12-30	2001-07-16	Judith K. Gwathmey	Iron chelator delivery system
CA2313270C (fr) *	2000-06-30	2011-09-13	Apotex Inc.	Utilisation de deferiprone pour le traitement et la prevention de maladies cardiaques induites par le fer
US20040101521A1 (en)	2002-07-12	2004-05-27	The Buck Institute For Research On Aging	Iron sequestration or elimination to reduce neurodegeneration or Parkinsons disease progression
US7985422B2 (en)	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
US8268352B2 (en)	2002-08-05	2012-09-18	Torrent Pharmaceuticals Limited	Modified release composition for highly soluble drugs
JP4757024B2 (ja)	2002-11-07	2011-08-24	テクニオンリサーチアンドディベラップメントファウンデイションリミテッド	神経保護鉄キレート剤及びそれを含む医薬組成物
AU2005271455A1 (en) *	2004-08-06	2006-02-16	Shiva Biomedical, Llc	Iron chelators for treating radiocontrast-associated renal dysfunction
GB0502475D0 (en) *	2005-02-07	2005-03-16	Sb Pharmco Inc	Novel compositions
AU2007219009B2 (en)	2006-02-22	2012-12-20	Apotex Technologies Inc.	The use of deferiprone and methods to treat and/or prevent Friedreich Ataxia resulting from intracellular mishandling of iron
AU2007291509B2 (en) *	2006-08-30	2013-05-02	Jagotec Ag	Controlled release oral dosage formulations comprising a core and one or more barrier layers
WO2008027557A2 (fr) *	2006-08-31	2008-03-06	Spherics, Inc.	Compositions à base de topiramate et méthodes permettant d'en augmenter la biodisponibilité
US20080138440A1 (en) *	2006-11-29	2008-06-12	Cormedix Inc.	Methods of diagnosing and alleviating gadolinium toxicity
CN101352438A (zh)	2007-07-25	2009-01-28	复旦大学	去铁酮及其制剂在制备防治蒽环类药物心脏毒性药物中的用途
RS53689B1 (en)	2008-04-25	2015-04-30	Apotex Technologies Inc.	LIQUID FORMULATION OF DEFERIPRON WITH FAVORABLE TASTE
CA2726529A1 (fr)	2008-05-30	2009-12-23	University Of Cincinnati	Inhibition de la formation de biofilms a l'aide de chelateurs de zinc
WO2010005851A1 (fr)	2008-07-08	2010-01-14	Xenon Pharmaceuticals Inc.	Polythérapie destinée au traitement de troubles du fer
US20100255082A1 (en) *	2008-07-31	2010-10-07	Ishwar Chauhan	Functionally Coated Breakable Tablets
EP2206506A1 (fr)	2008-12-18	2010-07-14	Bracco Imaging S.p.A	Formulations probiotiques
UA103366C2 (ru)	2009-01-26	2013-10-10	Майкл Спіно	Применение деферипрона для лечения и профилактики связанных с железом глазных расстройств
US8603814B2 (en)	2009-07-20	2013-12-10	Rutgers The State University Of New Jersey	Method of inhibiting nonsense-mediated mRNA decay
US20120172292A1 (en)	2009-09-10	2012-07-05	New York University	Method for protection of antimicrobial and anticancer drugs from inactivation by nitric oxide
US8563035B2 (en) *	2010-05-05	2013-10-22	Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi	Oral tablet compositions of dexlansoprazole
IN2013MU01696A (fr)	2013-05-10	2015-06-26	Cipla Ltd
CN103476419A (zh) *	2011-01-07	2013-12-25	梅里翁第三研究有限公司	口服投药的含铁药物组合物
DE102011112898A1 (de)	2011-09-08	2013-03-14	Charité - Universitätsmedizin Berlin	Nanopartikuläres Phosphatadsorbens basierend auf Maghämit oder Maghämit/Magnetit, dessen Herstellung und Verwendungen
BR112014012054A2 (pt)	2011-11-18	2017-05-30	Apotex Tech Inc	métodos de tratamento com deferiprona
WO2013139931A1 (fr)	2012-03-21	2013-09-26	Icm (Institut Du Cerveau Et De La Moelle Épinière)	Composition destinée à être utilisée dans le traitement de maladies neurodégénératives ayant des syndromes parkinsoniens
US20150246027A1 (en)	2012-11-12	2015-09-03	Cipla Limited	Fixed dose pharmaceutical composition comprising deferasirox and deferiprone
US11331287B2 (en) *	2013-06-06	2022-05-17	Balchem Corporation	Iron supplement
ITMI20132066A1 (it)	2013-12-11	2015-06-12	Farmatron Ltd	Sistemi terapeutici a rilascio modificato per la somministrazione orale di mentolo nel trattamento delle malattie intestinali
CN109862892A (zh)	2016-08-05	2019-06-07	阿布费罗制药股份有限公司	用于治疗金属介导的病症的给药方案
US20180362228A1 (en)	2017-02-16	2018-12-20	Jeffrey D. Jacobson	Container closure with integrated utensil
CN114533689A (zh)	2017-10-25	2022-05-27	奇斯药制品公司	延迟释放去铁酮片剂及其使用方法

2018
- 2018-10-25 CN CN202210164525.3A patent/CN114533689A/zh active Pending
- 2018-10-25 MX MX2020004107A patent/MX2020004107A/es unknown
- 2018-10-25 BR BR112020008128-0A patent/BR112020008128A2/pt unknown
- 2018-10-25 US US16/759,254 patent/US20200253945A1/en not_active Abandoned
- 2018-10-25 EP EP18871663.3A patent/EP3684344A4/fr active Pending
- 2018-10-25 NZ NZ763555A patent/NZ763555A/en unknown
- 2018-10-25 SG SG11202003153TA patent/SG11202003153TA/en unknown
- 2018-10-25 CA CA3077514A patent/CA3077514C/fr not_active Expired - Fee Related
- 2018-10-25 JP JP2020523267A patent/JP7246384B2/ja active Active
- 2018-10-25 UA UAA202003078A patent/UA126977C2/uk unknown
- 2018-10-25 KR KR1020207014502A patent/KR102624627B1/ko active IP Right Grant
- 2018-10-25 AU AU2018357350A patent/AU2018357350B2/en active Active
- 2018-10-25 CN CN201880069331.7A patent/CN111918646B/zh active Active
- 2018-10-25 US US16/171,173 patent/US10780055B2/en active Active
- 2018-10-25 CA CA3172668A patent/CA3172668A1/fr not_active Withdrawn
- 2018-10-25 US US16/171,170 patent/US10940116B2/en active Active
- 2018-10-25 MA MA050201A patent/MA50201A/fr unknown
- 2018-10-25 WO PCT/IB2018/058350 patent/WO2019082128A1/fr active Application Filing
2019
- 2019-12-13 US US16/714,520 patent/US11458103B2/en active Active
2020
- 2020-04-03 US US16/839,928 patent/US11357731B2/en active Active
- 2020-04-13 IL IL273955A patent/IL273955A/en unknown
- 2020-04-20 PH PH12020550815A patent/PH12020550815A1/en unknown
- 2020-04-21 SA SA520411808A patent/SA520411808B1/ar unknown
- 2020-05-12 US US15/930,373 patent/US10940115B2/en active Active
2021
- 2021-05-21 US US17/327,135 patent/US11723874B2/en active Active
2022
- 2022-05-12 US US17/742,960 patent/US11607389B2/en active Active

Also Published As

Publication number	Publication date
WO2019082128A1 (fr)	2019-05-02
JP7246384B2 (ja)	2023-03-27
CN111918646A (zh)	2020-11-10
EP3684344A1 (fr)	2020-07-29
PH12020550815A1 (en)	2021-07-05
IL273955A (en)	2020-05-31
UA126977C2 (uk)	2023-03-01
US11723874B2 (en)	2023-08-15
CN111918646B (zh)	2022-02-22
BR112020008128A2 (pt)	2020-11-03
KR20200077542A (ko)	2020-06-30
CN114533689A (zh)	2022-05-27
US20190117581A1 (en)	2019-04-25
US11357731B2 (en)	2022-06-14
SA520411808B1 (ar)	2023-02-16
US10940116B2 (en)	2021-03-09
US20220265559A1 (en)	2022-08-25
CA3077514C (fr)	2022-10-11
AU2018357350B2 (en)	2023-09-21
SG11202003153TA (en)	2020-05-28
US11458103B2 (en)	2022-10-04
EP3684344A4 (fr)	2020-11-18
US20190125682A1 (en)	2019-05-02
US20200188309A1 (en)	2020-06-18
CA3077514A1 (fr)	2019-05-02
US20200268672A1 (en)	2020-08-27
US20200253945A1 (en)	2020-08-13
MX2020004107A (es)	2020-07-24
US11607389B2 (en)	2023-03-21
US20210386677A1 (en)	2021-12-16
AU2018357350A1 (en)	2020-04-30
NZ763555A (en)	2022-07-01
JP2021500377A (ja)	2021-01-07
US10780055B2 (en)	2020-09-22
KR102624627B1 (ko)	2024-01-16
US10940115B2 (en)	2021-03-09
US20200237674A1 (en)	2020-07-30
CA3172668A1 (fr)	2019-05-02

Publication	Publication Date	Title
MA50201A (fr)	2021-04-28	Comprimés de défériprone à libération retardée et procédés d'utilisation correspondants
MA50077A (fr)	2020-07-15	Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA43018A (fr)	2021-06-02	Anticorps anti-pd1 et procédés d'utilisation
MA42043A (fr)	2018-03-14	Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA44524A (fr)	2019-02-06	Néoantigènes et leurs procédés d'utilisation
MA48772A (fr)	2020-04-08	Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA45280A (fr)	2019-01-09	Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation
MA46529A (fr)	2019-08-21	Anticorps anti-lag-3 et leurs procédés d'utilisation
MA49950A (fr)	2020-07-01	Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA50948A (fr)	2020-10-14	Anticorps et procédés d'utilisation de ceux-ci
MA50956A (fr)	2020-10-14	Anticorps anti-cd137 et procédés d'utilisation correspondants
MA43802A (fr)	2018-11-28	Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci
MA43389A (fr)	2021-05-12	Anticorps anti-ox40 et leurs procédés d'utilisation
MA47499A (fr)	2019-12-25	Anticorps anti-tau et leurs procédés d'utilisation
MA44990A (fr)	2021-04-07	Polythérapies d'inhibiteurs de hdac et d'inhibiteurs de pd-l1
MA44740A (fr)	2019-02-27	Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
MA50636A (fr)	2021-04-14	Compositions et procédés pour inhiber l'activité d'arginase
MA46566A (fr)	2019-08-28	Oxystérols et leurs procédés d'utilisation
MA53355A (fr)	2022-03-16	Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA51552A (fr)	2021-03-24	Anticorps anti-ox40 et procédés d'utilisation
MA46565A (fr)	2019-08-28	Oxystérols et leurs procédés d'utilisation
MA55097A (fr)	2022-01-05	Oxystérols et leurs procédés d'utilisation
MA43365A (fr)	2018-10-10	Anticorps anti-dr5 et procédés d'utilisation de ceux-ci
MA54851A (fr)	2021-12-08	Oxystérols et leurs procédés d'utilisation
MA41951A (fr)	2018-02-28	Gènes insecticides et procédés d'utilisation